Lapatinib (BioDeep_00000019028)

   

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulphonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine

化学式: C29H26ClFN4O4S (580.1347238000001)
中文名称: 拉帕替尼
谱图信息: 最多检出来源 Homo sapiens(blood) 55.56%

分子结构信息

SMILES: CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1
InChI: InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)

描述信息

Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine. Lapatinib is human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EH - Human epidermal growth factor receptor 2 (her2) tyrosine kinase inhibitors
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163760 - HER2-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159156 - HER2 Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
D000970 - Antineoplastic Agents

同义名列表

13 个代谢物同义名

N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulphonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine; N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine; N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-(3-Chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine; N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; Lapatinib tosilate hydrate; Lapatinib ditosylate; GW 572016; Lapatinib; GW572016; Tykerb; FMM



数据库引用编号

13 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(5)

BioCyc(0)

PlantCyc(0)

代谢反应

3 个相关的代谢反应过程信息。

Reactome(3)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Chien-Yi Ho, Cheng-Yen Wei, Ruo-Wen Zhao, Yi-Lun Ye, Hui-Chi Huang, Jen-Chih Lee, Fang-Ju Cheng, Wei-Chien Huang. Artemisia argyi extracts overcome lapatinib resistance via enhancing TMPRSS2 activation in HER2-positive breast cancer. Environmental toxicology. 2024 Jun; 39(6):3389-3399. doi: 10.1002/tox.24202. [PMID: 38445457]
  • Jing Zhao, Dongming Yan, Yue Li, Xiaoqing Xu, Fengling Li, Shuang Zhang, Jingyi Jin, Furong Qiu. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2024 Apr; 1237(?):124100. doi: 10.1016/j.jchromb.2024.124100. [PMID: 38547701]
  • Yunjie Chen, Suyan Zhu, Zhu Lin, Yuanbin Zhang, Cheng Jin, Shengqu He, Xueqin Chen, Xuan Zhou. Metformin alleviates ethanol-induced cardiomyocyte injury by activating AKT/Nrf2 signaling in an ErbB2-dependent manner. Molecular biology reports. 2023 Feb; ?(?):. doi: 10.1007/s11033-023-08310-x. [PMID: 36765018]
  • Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li. Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review. PloS one. 2023; 18(1):e0279775. doi: 10.1371/journal.pone.0279775. [PMID: 36602979]
  • Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li. Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis. Systematic reviews. 2022 Dec; 11(1):264. doi: 10.1186/s13643-022-02134-9. [PMID: 36496473]
  • Majed Alrobaian, Sagar Suman Panda, Waleed H Almalki, Obaid Afzal, Imran Kazmi, Manal A Alossaimi, Fahad A Al-Abbasi, Hanadi A Katouah, Rehan A Rub, B V V Ravi Kumar, Mahfoozur Rahman, Sarwar Beg. Development and Validation of Chemometrics-Assisted Green UPLC-MS/MS Bioanalytical Method for Simultaneous Estimation of Capecitabine and Lapatinib in Rat Plasma. Journal of chromatographic science. 2022 Jul; 60(6):559-570. doi: 10.1093/chromsci/bmab094. [PMID: 34318311]
  • Hongxia Gong, Yun Su, Lixia Zhao, Li Ma, Liying Zhang, Liangying Hou, Tingting Li, Shiwei Niu, Han Zhang, Chenghao Li, Xiaojie Jin, Long Ge, Guangxian Leng, Yongqi Liu. Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis. Journal of clinical pharmacy and therapeutics. 2022 Apr; 47(4):493-506. doi: 10.1111/jcpt.13570. [PMID: 34796971]
  • Parham Jabbarzadeh Kaboli, Shuang Luo, Yao Chen, Masume Jomhori, Saber Imani, Shixin Xiang, Zhigui Wu, Mingxing Li, Jing Shen, Yueshui Zhao, Xu Wu, Chi Hin Cho, Zhangang Xiao. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress. Gene. 2022 Mar; 816(?):146171. doi: 10.1016/j.gene.2021.146171. [PMID: 35026293]
  • Kamonpan Sanachai, Tuanjai Somboon, Patcharin Wilasluck, Peerapon Deetanya, Peter Wolschann, Thierry Langer, Vannajan Sanghiran Lee, Kittikhun Wangkanont, Thanyada Rungrotmongkol, Supot Hannongbua. Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening. PloS one. 2022; 17(6):e0269563. doi: 10.1371/journal.pone.0269563. [PMID: 35771802]
  • M H Raymonda, J H Ciesla, M Monaghan, J Leach, G Asantewaa, L A Smorodintsev-Schiller, M M Lutz, X L Schafer, T Takimoto, S Dewhurst, J Munger, I S Harris. Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro. Virology. 2022 01; 566(?):60-68. doi: 10.1016/j.virol.2021.11.008. [PMID: 34871905]
  • Rina Agustina, Yusuke Masuo, Yasuto Kido, Kyosuke Shinoda, Takahiro Ishimoto, Yukio Kato. Identification of Food-Derived Isoflavone Sulfates as Inhibition Markers for Intestinal Breast Cancer Resistance Proteins. Drug metabolism and disposition: the biological fate of chemicals. 2021 11; 49(11):972-984. doi: 10.1124/dmd.121.000534. [PMID: 34413161]
  • Maobo Huang, Yuanfei Zhou, Dongzhu Duan, Chuanyu Yang, Zhongmei Zhou, Fubing Li, Yanjie Kong, Yi-Ching Hsieh, Ruihan Zhang, Wenping Ding, Weilie Xiao, PemaTenzin Puno, Ceshi Chen. Targeting ubiquitin conjugating enzyme UbcH5b by a triterpenoid PC3-15 from Schisandra plants sensitizes triple-negative breast cancer cells to lapatinib. Cancer letters. 2021 04; 504(?):125-136. doi: 10.1016/j.canlet.2021.02.009. [PMID: 33607208]
  • Binghe Xu, Min Yan, Fei Ma, Xichun Hu, Jifeng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Yuanting Gu, Qianjun Chen, Jinping Liu, Jing Cheng, Cuizhi Geng, Shukui Qin, Shusen Wang, Jinsong Lu, Kunwei Shen, Qiang Liu, Xiaojia Wang, Hong Wang, Ting Luo, Jin Yang, Yudong Wu, Zhiyong Yu, Xiaoyu Zhu, Chunxia Chen, Jianjun Zou. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet. Oncology. 2021 03; 22(3):351-360. doi: 10.1016/s1470-2045(20)30702-6. [PMID: 33581774]
  • Monika Lavan, Xueqi Wang, Robyn McCain, Amber Jannasch, Bruce Cooper, Scott Hostetler, Stephen Byrn, Gregory Knipp. Development of a Pediatric Mini-Tablet Formulation for Expedited Preclinical Studies. AAPS PharmSciTech. 2021 Jan; 22(1):40. doi: 10.1208/s12249-020-01891-x. [PMID: 33417081]
  • Mohammad M Ghahremanpour, Julian Tirado-Rives, Maya Deshmukh, Joseph A Ippolito, Chun-Hui Zhang, Israel Cabeza de Vaca, Maria-Elena Liosi, Karen S Anderson, William L Jorgensen. Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2. ACS medicinal chemistry letters. 2020 Dec; 11(12):2526-2533. doi: 10.1021/acsmedchemlett.0c00521. [PMID: 33324471]
  • Ignacio Vayá, Inmaculada Andreu, Emilio Lence, Concepción González-Bello, M Consuelo Cuquerella, Miriam Navarrete-Miguel, Daniel Roca-Sanjuán, Miguel A Miranda. Characterization of Locally Excited and Charge-Transfer States of the Anticancer Drug Lapatinib by Ultrafast Spectroscopy and Computational Studies. Chemistry (Weinheim an der Bergstrasse, Germany). 2020 Dec; 26(68):15922-15930. doi: 10.1002/chem.202001336. [PMID: 32585059]
  • Meng-Na Wang, Yun Kuang, Li-Ying Gong, Ye Hua, Qi Pei, Cheng-Xian Guo, Yu Cao, Jie Huang, Guo-Ping Yang. First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects. Investigational new drugs. 2020 12; 38(6):1826-1835. doi: 10.1007/s10637-020-00959-6. [PMID: 32535812]
  • Moe Tsuda, Hiroshi Ishiguro, Naoko Toriguchi, Norikazu Masuda, Hiroko Bando, Masahiro Ohgami, Masato Homma, Satoshi Morita, Naohito Yamamoto, Katsumasa Kuroi, Yasuhiro Yanagita, Toshimi Takano, Satoru Shimizu, Masakazu Toi. Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial. Cancer medicine. 2020 12; 9(24):9246-9255. doi: 10.1002/cam4.3528. [PMID: 33094919]
  • Prashanth Moku, Lois Shepherd, Suhail M Ali, Kim Leitzel, Wendy R Parulekar, Liting Zhu, Shakeel Virk, Dora Nomikos, Samuel Aparicio, Karen Gelmon, Joe Drabick, Leah Cream, E Scott Halstead, Todd M Umstead, Dan Mckeone, Hyma Polimera, Ashok Maddukuri, Aamnah Ali, Vinod Nagabhairu, Joyson Poulose, Neha Pancholy, Howard Spiegel, Bingshu E Chen, Allan Lipton. Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial. Cancer. 2020 11; 126(22):4859-4866. doi: 10.1002/cncr.33149. [PMID: 32910476]
  • Ivan Haralampiev, Diego Javier Alonso de Armiño, Meike Luck, Markus Fischer, Tobias Abel, Daniel Huster, Santiago Di Lella, Holger A Scheidt, Peter Müller. Interaction of the small-molecule kinase inhibitors tofacitinib and lapatinib with membranes. Biochimica et biophysica acta. Biomembranes. 2020 11; 1862(11):183414. doi: 10.1016/j.bbamem.2020.183414. [PMID: 32710852]
  • Parvaneh Peyvand, Zahra Vaezi, Mosslim Sedghi, Nima Dalir, Leila Ma'mani, Hossein Naderi-Manesh. Imidazolium-based ionic liquid functionalized mesoporous silica nanoparticles as a promising nano-carrier: response surface strategy to investigate and optimize loading and release process for Lapatinib delivery. Pharmaceutical development and technology. 2020 Nov; 25(9):1150-1161. doi: 10.1080/10837450.2020.1803909. [PMID: 32746669]
  • Jonathan E Tsang, Lorenz M Urner, Gyudong Kim, Kingsley Chow, Lynn Baufeld, Kym Faull, Timothy F Cloughesy, Peter M Clark, Michael E Jung, David A Nathanson. Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors. ACS medicinal chemistry letters. 2020 Oct; 11(10):1799-1809. doi: 10.1021/acsmedchemlett.9b00599. [PMID: 33062157]
  • Richard Howley, Matthew Mansi, Janhavi Shinde, Juliana Restrepo, Bin Chen. Evaluation of aminolevulinic acid-mediated protoporphyrin IX fluorescence and enhancement by ABCG2 inhibitors in renal cell carcinoma cells. Journal of photochemistry and photobiology. B, Biology. 2020 Oct; 211(?):112017. doi: 10.1016/j.jphotobiol.2020.112017. [PMID: 32919173]
  • Hany W Darwish, Ahmed H Bakheit, Nasser S Al-Shakliah, Ibrahim A Darwish. Development of innovative artificial neural networks for simultaneous determination of lapatinib and foretinib in human urine by micellar enhanced synchronous spectrofluorimetry. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. 2020 Sep; 238(?):118438. doi: 10.1016/j.saa.2020.118438. [PMID: 32388416]
  • Fei Xu, Kaping Lee, Wen Xia, Hai Liao, Qianyi Lu, Jingmin Zhang, Huimin Yuan, Kai Zhang, Qiufan Zheng, Ge Qin, Qinglian Zhai, Ruoxi Hong, Kuikui Jiang, Yuan Li, Shusen Wang. Administration of Lapatinib with Food Increases Its Plasma Concentration in Chinese Patients with Metastatic Breast Cancer: A Prospective Phase II Study. The oncologist. 2020 09; 25(9):e1286-e1291. doi: 10.1634/theoncologist.2020-0044. [PMID: 32058619]
  • Shuo Zhou, Ziyuan Zhou, Kai Ding, Yaxia Yuan, Charles Loftin, Fang Zheng, Chang-Guo Zhan. DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1. Scientific reports. 2020 06; 10(1):10187. doi: 10.1038/s41598-020-67283-0. [PMID: 32576928]
  • Abhinav R Saxena, Zoran Ilic, Veda Sripada, Dana R Crawford. Lower concentrations of curcumin inhibit Her2-Akt pathway components in human breast cancer cells, and other dietary botanicals potentiate this and lapatinib inhibition. Nutrition research (New York, N.Y.). 2020 06; 78(?):93-104. doi: 10.1016/j.nutres.2020.05.007. [PMID: 32563955]
  • Agnieszka Karbownik, Katarzyna Sobańska, Włodzimierz Płotek, Tomasz Grabowski, Agnieszka Klupczynska, Szymon Plewa, Edmund Grześkowiak, Edyta Szałek. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid. Investigational new drugs. 2020 06; 38(3):574-583. doi: 10.1007/s10637-019-00806-3. [PMID: 31177402]
  • Bronwen J Mayo, Kate R Secombe, Anthony D Wignall, Emma Bateman, Daniel Thorpe, Claudio Pietra, Dorothy M Keefe, Joanne M Bowen. The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats. Cancer chemotherapy and pharmacology. 2020 04; 85(4):793-803. doi: 10.1007/s00280-020-04040-0. [PMID: 32060615]
  • Jun Wang, Feng-Mei Lv, Dong-Li Wang, Jian-Liang Du, Hai-Yan Guo, Hai-Ni Chen, Shou-Jin Zhao, Zhe-Peng Liu, Yu Liu. Synergistic Antitumor Effects on Drug-Resistant Breast Cancer of Paclitaxel/Lapatinib Composite Nanocrystals. Molecules (Basel, Switzerland). 2020 Jan; 25(3):. doi: 10.3390/molecules25030604. [PMID: 32019194]
  • Kentaro Ando, Takeshi Wada, Xin Cao. Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models. Scientific reports. 2020 01; 10(1):738. doi: 10.1038/s41598-020-57601-x. [PMID: 31959820]
  • Hany W Darwish, Ahmed H Bakheit, Nasser S Al-Shakliah, A F M Motiur Rahman, Ibrahim A Darwish. Experimental and computational evaluation of kolliphor RH 40 as a new fluorescence enhancer in development of a micellar-based spectrofluorimetric method for determination of lapatinib in tablets and urine. PloS one. 2020; 15(12):e0239918. doi: 10.1371/journal.pone.0239918. [PMID: 33270656]
  • Mohamed W Attwa, Adnan A Kadi, Ali S Abdelhameed, Hassan A Alhazmi. Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies. Drug design, development and therapy. 2020; 14(?):783-793. doi: 10.2147/dddt.s239458. [PMID: 32158196]
  • Jonathan D Strope, Cody J Peer, Tristan M Sissung, O Morgan Hall, Phoebe A Huang, Emily M Harris, Kirk R Gustafson, Curtis J Henrich, Dina M Sigano, Gary T Pauly, Joel P Schneider, Susan E Bates, William D Figg. Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain. Cancer biology & therapy. 2020; 21(3):223-230. doi: 10.1080/15384047.2019.1683324. [PMID: 31709896]
  • Terry W Moody, Lingaku Lee, Irene Ramos-Alvarez, Robert T Jensen. Neurotensin receptors regulate transactivation of the EGFR and HER2 in a reactive oxygen species-dependent manner. European journal of pharmacology. 2019 Dec; 865(?):172735. doi: 10.1016/j.ejphar.2019.172735. [PMID: 31614143]
  • Zhi Xu, Shi-Jia Zhao, Yi Liu. 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. European journal of medicinal chemistry. 2019 Dec; 183(?):111700. doi: 10.1016/j.ejmech.2019.111700. [PMID: 31546197]
  • Sudhakar M Pai, Philip Chaikin, Jolene Kay Berg. Pharmacokinetics of Lapatinib, a Nonrenally Cleared Drug, in Patients With End-Stage Renal Disease on Maintenance Hemodialysis. Journal of clinical pharmacology. 2019 10; 59(10):1379-1383. doi: 10.1002/jcph.1430. [PMID: 31074516]
  • Gwendolen Lorch, Karthigayini Sivaprakasam, Victoria Zismann, Nieves Perdigones, Tania Contente-Cuomo, Alexandra Nazareno, Salvatore Facista, Shukmei Wong, Kevin Drenner, Winnie S Liang, Joseph M Amann, Sara L Sinicropi-Yao, Michael J Koenig, Krista La Perle, Timothy G Whitsett, Muhammed Murtaza, Jeffrey M Trent, David P Carbone, William P D Hendricks. Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 10; 25(19):5866-5877. doi: 10.1158/1078-0432.ccr-19-1145. [PMID: 31431454]
  • Dandan Zhou, Linghua Kong, Yiguo Jiang, Cheng Wang, Yao Ni, Yedong Wang, Hongjian Zhang, Jianqing Ruan. UGT-dependent regioselective glucuronidation of ursodeoxycholic acid and obeticholic acid and selective transport of the consequent acyl glucuronides by OATP1B1 and 1B3. Chemico-biological interactions. 2019 Sep; 310(?):108745. doi: 10.1016/j.cbi.2019.108745. [PMID: 31299240]
  • Sarrah E Widatalla, Olga Y Korolkova, Diva S Whalen, J Shawn Goodwin, Kevin P Williams, Josiah Ochieng, Amos M Sakwe. Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors. Carcinogenesis. 2019 08; 40(8):998-1009. doi: 10.1093/carcin/bgy192. [PMID: 30590459]
  • Yuko Asari, Kazunori Kageyama, Aya Sugiyama, Hikaru Kogawa, Kanako Niioka, Makoto Daimon. Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells. Endocrine journal. 2019 Jun; 66(6):515-522. doi: 10.1507/endocrj.ej18-0491. [PMID: 30880293]
  • Françoise Rothé, Maria Joao Silva, David Venet, Christine Campbell, Ian Bradburry, Ghizlane Rouas, Evandro de Azambuja, Marion Maetens, Debora Fumagalli, Vanessa Rodrik-Outmezguine, Serena Di Cosimo, Daniela Rosa, Stephen Chia, Andrew Wardley, Takayuki Ueno, Wolfgang Janni, Jens Huober, Jose Baselga, Martine Piccart, Sherene Loi, Christos Sotiriou, Sarah-Jane Dawson, Michail Ignatiadis. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 06; 25(12):3581-3588. doi: 10.1158/1078-0432.ccr-18-2521. [PMID: 30862692]
  • Parham Jabbarzadeh Kaboli, Melody Pui-Yee Leong, Patimah Ismail, King-Hwa Ling. Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study. Pharmacological reports : PR. 2019 Feb; 71(1):13-23. doi: 10.1016/j.pharep.2018.07.005. [PMID: 30343043]
  • Jaekwang Jeong, Jungmin Choi, Wonnam Kim, Pamela Dann, Farzin Takyar, Julia V Gefter, Peter A Friedman, John J Wysolmerski. Inhibition of ezrin causes PKCα-mediated internalization of erbb2/HER2 tyrosine kinase in breast cancer cells. The Journal of biological chemistry. 2019 01; 294(3):887-901. doi: 10.1074/jbc.ra118.004143. [PMID: 30463939]
  • Gloria E Villalpando-Rodriguez, Anna R Blankstein, Carmen Konzelman, Spencer B Gibson. Lysosomal Destabilizing Drug Siramesine and the Dual Tyrosine Kinase Inhibitor Lapatinib Induce a Synergistic Ferroptosis through Reduced Heme Oxygenase-1 (HO-1) Levels. Oxidative medicine and cellular longevity. 2019; 2019(?):9561281. doi: 10.1155/2019/9561281. [PMID: 31636810]
  • Yi Ding, Chang Gong, De Huang, Rui Chen, Pinpin Sui, Kevin H Lin, Gehao Liang, Lifeng Yuan, Handan Xiang, Junying Chen, Tao Yin, Peter B Alexander, Qian-Fei Wang, Er-Wei Song, Qi-Jing Li, Kris C Wood, Xiao-Fan Wang. Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers. Nature communications. 2018 10; 9(1):4274. doi: 10.1038/s41467-018-06651-x. [PMID: 30323337]
  • Geralyn P Kocan, Mike Qingtao Huang, Fumin Li, Sudhakar Pai. A sensitive LC-MS-MS assay for the determination of lapatinib in human plasma in subjects with end-stage renal disease receiving hemodialysis. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2018 Oct; 1097-1098(?):74-82. doi: 10.1016/j.jchromb.2018.09.005. [PMID: 30205234]
  • Agnieszka Karbownik, Edyta Szałek, Katarzyna Sobańska, Tomasz Grabowski, Agnieszka Klupczynska, Szymon Plewa, Anna Wolc, Magdalena Magiera, Joanna Porażka, Zenon J Kokot, Edmund Grześkowiak. The concomitant use of lapatinib and paracetamol - the risk of interaction. Investigational new drugs. 2018 10; 36(5):819-827. doi: 10.1007/s10637-018-0573-1. [PMID: 29464465]
  • Richa Shrivastava, Shruti Trivedi, Pankaj Kumar Singh, Mohammad Asif, Manish Kumar Chourasia, Amit Khanna, Smrati Bhadauria. Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity. Biochemical and biophysical research communications. 2018 09; 503(2):677-683. doi: 10.1016/j.bbrc.2018.06.060. [PMID: 29908185]
  • Giulia Siravegna, Luca Lazzari, Giovanni Crisafulli, Andrea Sartore-Bianchi, Benedetta Mussolin, Andrea Cassingena, Cosimo Martino, Richard B Lanman, Rebecca J Nagy, Stephen Fairclough, Giuseppe Rospo, Giorgio Corti, Alice Bartolini, Pamela Arcella, Monica Montone, Francesca Lodi, Annalisa Lorenzato, Alice Vanzati, Emanuele Valtorta, Giovanni Cappello, Andrea Bertotti, Sara Lonardi, Vittorina Zagonel, Francesco Leone, Mariangela Russo, Antonella Balsamo, Mauro Truini, Federica Di Nicolantonio, Alessio Amatu, Erica Bonazzina, Silvia Ghezzi, Daniele Regge, Angelo Vanzulli, Livio Trusolino, Salvatore Siena, Silvia Marsoni, Alberto Bardelli. Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. Cancer cell. 2018 07; 34(1):148-162.e7. doi: 10.1016/j.ccell.2018.06.004. [PMID: 29990497]
  • C F Spraggs, L R Parham, L P Briley, L Warren, L S Williams, D J Fraser, Z Jiang, Z Aziz, S Ahmed, G Demetriou, A Mehta, N Jackson, J Byrne, M Andersson, M Toi, L Harris, J Gralow, J A Zujewski, R Crescenzo, A Armour, E Perez, M Piccart. Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes. The pharmacogenomics journal. 2018 05; 18(3):480-486. doi: 10.1038/tpj.2017.39. [PMID: 28786423]
  • Tsuyoshi Karibe, Tomoki Imaoka, Koji Abe, Osamu Ando. Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys. Drug metabolism and disposition: the biological fate of chemicals. 2018 05; 46(5):667-679. doi: 10.1124/dmd.117.078931. [PMID: 29358184]
  • Gunjan Vasant Bonde, Sarita Kumari Yadav, Sheetal Chauhan, Pooja Mittal, Gufran Ajmal, Sathish Thokala, Brahmeshwar Mishra. Lapatinib nano-delivery systems: a promising future for breast cancer treatment. Expert opinion on drug delivery. 2018 05; 15(5):495-507. doi: 10.1080/17425247.2018.1449832. [PMID: 29521126]
  • Agnieszka Karbownik, Edyta Szałek, Katarzyna Sobańska, Agnieszka Klupczynska, Szymon Plewa, Tomasz Grabowski, Anna Wolc, Marta Moch, Zenon J Kokot, Edmund Grześkowiak. A pharmacokinetic study on lapatinib in type 2 diabetic rats. Pharmacological reports : PR. 2018 Apr; 70(2):191-195. doi: 10.1016/j.pharep.2017.09.003. [PMID: 29471066]
  • S T Kim, K C Banks, E Pectasides, S Y Kim, K Kim, R B Lanman, A Talasaz, J An, M G Choi, J H Lee, T S Sohn, J M Bae, S Kim, S H Park, J O Park, Y S Park, H Y Lim, N K D Kim, W Park, H Lee, A J Bass, K Kim, W K Kang, J Lee. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 04; 29(4):1037-1048. doi: 10.1093/annonc/mdy034. [PMID: 29409051]
  • Xiao-Dong Jiao, Chunming Ding, Yuan-Sheng Zang, Guanzhen Yu. Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report. BMC cancer. 2018 02; 18(1):206. doi: 10.1186/s12885-018-4116-0. [PMID: 29463236]
  • Jaume Albiol-Chiva, Josep Esteve-Romero, Juan Peris-Vicente. Development of a method to determine axitinib, lapatinib and afatinib in plasma by micellar liquid chromatography and validation by the European Medicines Agency guidelines. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2018 Feb; 1074-1075(?):61-69. doi: 10.1016/j.jchromb.2017.12.034. [PMID: 29331859]
  • Kevin M Koch, E Claire Dees, Shodeinde A Coker, Nandi J Reddy, Shelby D Gainer, Nikita Arya, Andrew P Beelen, Lionel D Lewis. The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer. Cancer chemotherapy and pharmacology. 2017 Dec; 80(6):1141-1146. doi: 10.1007/s00280-017-3470-y. [PMID: 29098381]
  • Amanda M Goodman, Oara Neumann, Kamilla Nørregaard, Luke Henderson, Mi-Ran Choi, Susan E Clare, Naomi J Halas. Near-infrared remotely triggered drug-release strategies for cancer treatment. Proceedings of the National Academy of Sciences of the United States of America. 2017 11; 114(47):12419-12424. doi: 10.1073/pnas.1713137114. [PMID: 29109274]
  • Chisa Furukawa, Naoko Fujii, Aya Manabe, Toshiyuki Matsunaga, Satoshi Endo, Hajime Hasegawa, Yoshinori Ito, Masahiko Yamaguchi, Yasuhiro Yamazaki, Akira Ikari. Up-Regulation of Transient Receptor Potential Melastatin 6 Channel Expression by Tumor Necrosis Factor-α in the Presence of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Journal of cellular physiology. 2017 Oct; 232(10):2841-2850. doi: 10.1002/jcp.25709. [PMID: 27925186]
  • Diep Ho, Jessica Huang, Judith-Anne W Chapman, Kim Leitzel, Suhail M Ali, Lois Shepherd, Wendy R Parulekar, Catherine E Ellis, Rocco J Crescnzo, Liting Zhu, Shakeel Virk, Dora Nomikos, Samuel Aparicio, Karen A Gelmon, Walter P Carney, Allan Lipton. Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab). Breast cancer research and treatment. 2017 Aug; 164(3):571-580. doi: 10.1007/s10549-017-4273-x. [PMID: 28484925]
  • Kristina M Havas, Vladislava Milchevskaya, Ksenija Radic, Ashna Alladin, Eleni Kafkia, Marta Garcia, Jens Stolte, Bernd Klaus, Nicole Rotmensz, Toby J Gibson, Barbara Burwinkel, Andreas Schneeweiss, Giancarlo Pruneri, Kiran R Patil, Rocio Sotillo, Martin Jechlinger. Metabolic shifts in residual breast cancer drive tumor recurrence. The Journal of clinical investigation. 2017 Jun; 127(6):2091-2105. doi: 10.1172/jci89914. [PMID: 28504653]
  • Hadir M Maher, Nourah Z Alzoman, Shereen M Shehata, Ashwag O Abahussain. UPLC-ESI-MS/MS study of the effect of green tea extract on the oral bioavailability of erlotinib and lapatinib in rats: Potential risk of pharmacokinetic interaction. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2017 Apr; 1049-1050(?):30-40. doi: 10.1016/j.jchromb.2017.02.029. [PMID: 28260629]
  • Terry W Moody, Irene Ramos-Alvarez, Paula Moreno, Samuel A Mantey, Lisa Ridnour, David Wink, Robert T Jensen. Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells. Peptides. 2017 04; 90(?):90-99. doi: 10.1016/j.peptides.2017.01.012. [PMID: 28153500]
  • Wen-Ji Zhang, Yong Li, Meng-Ning Wei, Yao Chen, Jian-Ge Qiu, Qi-Wei Jiang, Yang Yang, Di-Wei Zheng, Wu-Ming Qin, Jia-Rong Huang, Kun Wang, Wen-Juan Zhang, Yi-Jun Wang, Dong-Hua Yang, Zhe-Sheng Chen, Zhi Shi. Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer. Cancer letters. 2017 02; 386(?):100-109. doi: 10.1016/j.canlet.2016.11.011. [PMID: 27864115]
  • Jaekwang Jeong, Wonnam Kim, Lark Kyun Kim, Joshua VanHouten, John J Wysolmerski. HER2 signaling regulates HER2 localization and membrane retention. PloS one. 2017; 12(4):e0174849. doi: 10.1371/journal.pone.0174849. [PMID: 28369073]
  • Masahiro Ohgami, Masato Homma, Yoshiharu Suzuki, Kanako Naito, Motoko Yamada, Shoichi Mitsuhashi, Fumie Fujisawa, Hiroshi Kojima, Takayuki Kaburagi, Keiko Uchiumi, Yutaka Yamada, Hiroko Bando, Hisato Hara, Keiji Takei. A Simple High-Performance Liquid Chromatography for Determining Lapatinib and Erlotinib in Human Plasma. Therapeutic drug monitoring. 2016 12; 38(6):657-662. doi: 10.1097/ftd.00000000000003520. [PMID: 27851685]
  • Melissa J LaBonte, Dongyun Yang, Wu Zhang, Peter M Wilson, Yasir M Nagarwala, Kevin M Koch, Colleen Briner, Tomomi Kaneko, Sun-Young Rha, Oleg Gladkov, Susan G Urba, Dina Sakaeva, Michael J Pishvaian, Ruey-Kuen Hsieh, Wei-Ping Lee, Heinz-Josef Lenz. A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. Molecular cancer therapeutics. 2016 09; 15(9):2251-8. doi: 10.1158/1535-7163.mct-15-0908. [PMID: 27325685]
  • Ivo Vrobel, Hana Janečková, Edgar Faber, Kateřina Bouchalová, Kateřina Mičová, David Friedecký, Tomáš Adam. Ultrafast Online SPE-MS/MS Method for Quantification of 3 Tyrosine Kinase Inhibitors in Human Plasma. Therapeutic drug monitoring. 2016 08; 38(4):516-24. doi: 10.1097/ftd.0000000000000309. [PMID: 27414975]
  • Md Zahirul Kabir, Abdul Kadir Mukarram, Saharuddin B Mohamad, Zazali Alias, Saad Tayyab. Characterization of the binding of an anticancer drug, lapatinib to human serum albumin. Journal of photochemistry and photobiology. B, Biology. 2016 Jul; 160(?):229-39. doi: 10.1016/j.jphotobiol.2016.04.005. [PMID: 27128364]
  • Xu Wan, Xiaoyao Zheng, Xiaoyin Pang, Zhiqing Pang, Jingjing Zhao, Zheming Zhang, Tao Jiang, Wei Xu, Qizhi Zhang, Xinguo Jiang. Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain. Oncotarget. 2016 Jun; 7(23):34038-51. doi: 10.18632/oncotarget.8697. [PMID: 27086917]
  • Kari B Wisinski, Amye J Tevaarwerk, Mark E Burkard, Murtuza Rampurwala, Jens Eickhoff, Maria C Bell, Jill M Kolesar, Christopher Flynn, Glenn Liu. Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 06; 22(11):2659-67. doi: 10.1158/1078-0432.ccr-15-2365. [PMID: 27026198]
  • Chee Khoon Lee, Lucy Davies, Val J Gebski, Sarah J Lord, Angelo Di Leo, Stephen Johnston, Charles Geyer, David Cameron, Michael F Press, Catherine Ellis, Sherene Loi, Ian Marschner, John Simes, Paul de Souza. Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Mar; 34(9):936-44. doi: 10.1200/jco.2015.62.4767. [PMID: 26811533]
  • Young Seok Lee, Sun Goo Hwang, Jin Ki Kim, Tae Hwan Park, Young Rae Kim, Ho Sung Myeong, Jong Duck Choi, Kang Kwon, Cheol Seong Jang, Young Tae Ro, Yun Hee Noh, Sung Young Kim. Identification of novel therapeutic target genes in acquired lapatinib-resistant breast cancer by integrative meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016 Feb; 37(2):2285-97. doi: 10.1007/s13277-015-4033-7. [PMID: 26361955]
  • Kenichi Inoue, Katsumasa Kuroi, Satoru Shimizu, Yoshiaki Rai, Kenjiro Aogi, Norikazu Masuda, Takahiro Nakayama, Hiroji Iwata, Yuichiro Nishimura, Alison Armour, Yasutsuna Sasaki. Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer. International journal of clinical oncology. 2015 Dec; 20(6):1102-9. doi: 10.1007/s10147-015-0832-5. [PMID: 25967286]
  • Laura Cosmai, Maurizio Gallieni, Camillo Porta. Renal toxicity of anticancer agents targeting HER2 and EGFR. Journal of nephrology. 2015 Dec; 28(6):647-57. doi: 10.1007/s40620-015-0226-9. [PMID: 26341657]
  • Guo-Feng Shen, Ting-Ting Liu, Qi Wang, Min Jiang, Jie-Hua Shi. Spectroscopic and molecular docking studies of binding interaction of gefitinib, lapatinib and sunitinib with bovine serum albumin (BSA). Journal of photochemistry and photobiology. B, Biology. 2015 Dec; 153(?):380-90. doi: 10.1016/j.jphotobiol.2015.10.023. [PMID: 26555641]
  • Xu Wan, Xiaoyao Zheng, Xiaoying Pang, Zheming Zhang, Qizhi Zhang. Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer. Colloids and surfaces. B, Biointerfaces. 2015 Dec; 136(?):817-27. doi: 10.1016/j.colsurfb.2015.10.018. [PMID: 26539808]
  • Muhammed Murtaza, Sarah-Jane Dawson, Katherine Pogrebniak, Oscar M Rueda, Elena Provenzano, John Grant, Suet-Feung Chin, Dana W Y Tsui, Francesco Marass, Davina Gale, H Raza Ali, Pankti Shah, Tania Contente-Cuomo, Hossein Farahani, Karey Shumansky, Zoya Kingsbury, Sean Humphray, David Bentley, Sohrab P Shah, Matthew Wallis, Nitzan Rosenfeld, Carlos Caldas. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nature communications. 2015 Nov; 6(?):8760. doi: 10.1038/ncomms9760. [PMID: 26530965]
  • Zhi-Jun Huo, Shi-Jiang Wang, Zhi-Qi Wang, Wen-Shu Zuo, Ping Liu, Bo Pang, Kai Liu. Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation. Cancer science. 2015 Oct; 106(10):1429-37. doi: 10.1111/cas.12737. [PMID: 26177628]
  • Woan-Ruoh Lee, Shing-Chuan Shen, Yi-Hsien Shih, Chia-Lun Chou, Jonathan Te-Peng Tseng, Szu-Ying Chin, Kao-Hui Liu, Yen-Chou Chen, Ming-Chung Jiang. Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts. Journal of translational medicine. 2015 Jun; 13(?):191. doi: 10.1186/s12967-015-0553-6. [PMID: 26070816]
  • James N Wilson, Wenjun Liu, Adrienne S Brown, Ralf Landgraf. Binding-induced, turn-on fluorescence of the EGFR/ERBB kinase inhibitor, lapatinib. Organic & biomolecular chemistry. 2015 May; 13(17):5006-11. doi: 10.1039/c5ob00239g. [PMID: 25820099]
  • Xu Wan, Xiaoyao Zheng, Xiaoying Pang, Zheming Zhang, Tao Jing, Wei Xu, Qizhi Zhang. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. International journal of pharmaceutics. 2015 Apr; 484(1-2):16-28. doi: 10.1016/j.ijpharm.2015.02.037. [PMID: 25700543]
  • Aki Morikawa, David M Peereboom, Helen R Thorsheim, Ramakrishna Samala, Rajiv Balyan, Conleth G Murphy, Paul R Lockman, Ahkeem Simmons, Robert J Weil, Viviane Tabar, Patricia S Steeg, Quentin R Smith, Andrew D Seidman. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro-oncology. 2015 Feb; 17(2):289-95. doi: 10.1093/neuonc/nou141. [PMID: 25015089]
  • Angelika Kaczyńska, Joanna Świerczyńska, Anna Herman-Antosiewicz. Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates. Nutrition and cancer. 2015; 67(6):976-86. doi: 10.1080/01635581.2015.1053498. [PMID: 26134366]
  • Tetsuya Saita, Yuta Yamamoto, Masashi Shin, Yukitaka Nakano. Preparation of Antibodies and Development of an Enzyme-Linked Immunosorbent Assay for the Tyrosine Kinase Inhibitors Lapatinib and Nilotinib. Biological & pharmaceutical bulletin. 2015; 38(10):1652-7. doi: 10.1248/bpb.b15-00330. [PMID: 26424026]
  • Feiyan Lin, Shuanghu Wang, Yunfang Zhou, Chunmei Wu, Huilong Zou, Peiwu Geng, Qingwei Zhang, Xiuhua Zhang. Pharmacokinetic interaction study combining lapatinib with vorinostat in rats. Pharmacology. 2015; 95(3-4):160-5. doi: 10.1159/000380954. [PMID: 25896603]
  • Neil L Spector, Faith C Robertson, Sarah Bacus, Kimberly Blackwell, Deborah A Smith, Kelli Glenn, Leanne Cartee, Jennifer Harris, Carie L Kimbrough, Mark Gittelman, Eli Avisar, Peter Beitsch, Kevin M Koch. Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor. PloS one. 2015; 10(11):e0142845. doi: 10.1371/journal.pone.0142845. [PMID: 26571496]
  • Yasuyuki Yoshida, Tomoko Ozawa, Tsun-Wen Yao, Wang Shen, Dennis Brown, Andrew T Parsa, Jeffrey J Raizer, Shi-Yuan Cheng, Alexander H Stegh, Andrew P Mazar, Francis J Giles, Jann N Sarkaria, Nicholas Butowski, Theodore Nicolaides, C David James. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. Molecular cancer therapeutics. 2014 Dec; 13(12):2919-29. doi: 10.1158/1535-7163.mct-14-0306. [PMID: 25313012]
  • Jacek Musijowski, Monika Filist, Piotr J Rudzki. Sensitive single quadrupole LC/MS method for determination of lapatinib in human plasma. Acta poloniae pharmaceutica. 2014 Nov; 71(6):1029-36. doi: NULL. [PMID: 25745775]
  • Xuezhi Yang, Qingwei Zhang, Mengchun Chen, Lufeng Hu. Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats. Xenobiotica; the fate of foreign compounds in biological systems. 2014 Nov; 44(11):1009-13. doi: 10.3109/00498254.2014.919431. [PMID: 24831712]
  • Pierre Fumoleau, Kevin M Koch, Etienne Brain, François Lokiec, Keyvan Rezai, Ahmad Awada, Larry Hayward, Gustavo Werutsky, Jan Bogaerts, Sandrine Marréaud, Fatima Cardoso. A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). Breast (Edinburgh, Scotland). 2014 Oct; 23(5):663-9. doi: 10.1016/j.breast.2014.07.003. [PMID: 25065668]
  • Roumen Balansky, Alberto Izzotti, Francesco D'Agostini, Mariagrazia Longobardi, Rosanna T Micale, Sebastiano La Maestra, Anna Camoirano, Gancho Ganchev, Marietta Iltcheva, Vernon E Steele, Silvio De Flora. Assay of lapatinib in murine models of cigarette smoke carcinogenesis. Carcinogenesis. 2014 Oct; 35(10):2300-7. doi: 10.1093/carcin/bgu154. [PMID: 25053627]
  • Volkmar Müller, Stephan Gade, Bettina Steinbach, Sibylle Loibl, Gunter von Minckwitz, Michael Untch, Kathrin Schwedler, Kristina Lübbe, Christian Schem, Peter A Fasching, Christine Mau, Klaus Pantel, Heidi Schwarzenbach. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast cancer research and treatment. 2014 Aug; 147(1):61-8. doi: 10.1007/s10549-014-3079-3. [PMID: 25086636]
  • Vanesa Escudero-Ortiz, Juan José Pérez-Ruixo, Belén Valenzuela. Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice. Therapeutic drug monitoring. 2014 Jun; 36(3):317-25. doi: 10.1097/ftd.0000000000000027. [PMID: 24365980]
  • Li Zhang, Shuang Zhang, Shao-Bo Ruan, Qian-Yu Zhang, Qin He, Hui-le Gao. Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism. Acta pharmacologica Sinica. 2014 Jun; 35(6):846-52. doi: 10.1038/aps.2014.26. [PMID: 24902791]
  • A R Tan, A Dowlati, M N Stein, S F Jones, J R Infante, J Bendell, M P Kane, K T Levinson, A B Suttle, H A Burris. Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. British journal of cancer. 2014 May; 110(11):2647-54. doi: 10.1038/bjc.2014.233. [PMID: 24800949]
  • A Jo Chien, Pamela N Munster, Michelle E Melisko, Hope S Rugo, John W Park, Andrei Goga, Glenna Auerback, Elham Khanafshar, Karen Ordovas, Kevin M Koch, Mark M Moasser. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 May; 32(14):1472-9. doi: 10.1200/jco.2013.52.1161. [PMID: 24711549]
  • Megumi Inada-Inoue, Yuichi Ando, Kenji Kawada, Ayako Mitsuma, Masataka Sawaki, Taro Yokoyama, Yu Sunakawa, Hiroo Ishida, Kazuhiro Araki, Keishi Yamashita, Keiko Mizuno, Fumio Nagashima, Akiko Takekura, Kazuo Nagamatsu, Yasutsuna Sasaki. Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors. Cancer chemotherapy and pharmacology. 2014 Apr; 73(4):673-83. doi: 10.1007/s00280-014-2374-3. [PMID: 24464355]